Profil
Thomas F.
Widmann is the founder of Actelion Ltd. founded in 1999.
He is currently the Director at New York Philharmonic.
His former positions include Chairman-Supervisory Board at Immatics Biotechnologies GmbH from 2004 to 2009, Independent Director at Cancer Genetics, Inc. from 2017 to 2019, Director-Supervisory Board at Trigen Holdings AG in 2009, Director at Symetis SA, and General Partner at Wellington Partners GmbH from 2003 to 2017.
Dr. Widmann's education includes an undergraduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate from the University of Geneva.
Postes actifs de Thomas F. Widmann
| Sociétés | Poste | Début |
|---|---|---|
New York Philharmonic
New York Philharmonic Movies/EntertainmentConsumer Services Provides live theatrical presentations | Directeur/Membre du Conseil | - |
Anciens postes connus de Thomas F. Widmann
| Sociétés | Poste | Fin |
|---|---|---|
| CANCER GENETICS, INC. | Directeur/Membre du Conseil | 31/05/2019 |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Président | 12/11/2012 |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Develops drugs focusing on thrombosis and vascular dysfunction | Directeur/Membre du Conseil | 15/12/2009 |
| ACTELION | Fondateur | 01/01/2003 |
| SYMETIS SA | Directeur/Membre du Conseil | - |
Formation de Thomas F. Widmann
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Actelion Ltd.
Actelion Ltd. Pharmaceuticals: MajorHealth Technology Develops, produces and markets pharmaceutical drugs | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners invests in companies located in Germany, Europe and beyond. The firm focuses on life sciences companies. It provides financing for early and growth stage capital requirements with an investments size of EUR 2 - 20 million. It also acts as a lead and co-lead investor. | Finance |
Cancer Genetics, Inc.
Cancer Genetics, Inc. Medical SpecialtiesHealth Technology Provides cancer diagnostics and clinical services | Health Technology |
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Develops drugs focusing on thrombosis and vascular dysfunction | Commercial Services |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
New York Philharmonic
New York Philharmonic Movies/EntertainmentConsumer Services Provides live theatrical presentations | Consumer Services |
Ruprecht-Karls-Universität Heidelberg
Ruprecht-Karls-Universität Heidelberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Geneva
University of Geneva Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Symetis SA
Symetis SA BiotechnologyHealth Technology Develops products for pediatric cardio-vascular applications | Health Technology |
















